利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

221 条记录 (耗时 0.074 秒)

    METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR REACTIVE T CELLS FROM PERIPHERAL BLOOD
    72.
    发明申请
    METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR REACTIVE T CELLS FROM PERIPHERAL BLOOD 有权
    从外周血生成肿瘤反应性T细胞的人群的方法

    公开(公告)号：US20160008400A1

    公开(公告)日：2016-01-14

    申请号：US14771593

    申请日：2013-04-30

    申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES

    发明人： Alena Gros ,  Steven A. Rosenberg

    IPC分类号： A61K35/17 ,  C12N5/0783

    CPC分类号： A61K35/17 ,  C12N5/0636 ,  G01N33/5005 ,  G01N33/5094 ,  G01N33/56972

    摘要： Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.

    摘要翻译： 获得富集肿瘤反应性T细胞的细胞群的方法，所述方法包括：（a）从外周血样品获得外周血单核细胞（PBMC）的大量群体; （b）具体选择也从大量群体中表达PD-1和/或TIM-3的CD8 + T细胞; 和（c）将（b）中选择的细胞与未选择的细胞分离以获得富含肿瘤反应性T细胞的细胞群。 还公开了向哺乳动物施用富含肿瘤反应性T细胞的细胞群的相关方法，获得包含富含肿瘤反应性T细胞的细胞群以及分离或纯化的细胞群的药物组合物的方法。

    GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    74.
    发明申请
    GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE 审中-公开
    GP100特异性T细胞受体及相关材料及其使用方法

    公开(公告)号：US20140219978A1

    公开(公告)日：2014-08-07

    申请号：US14106031

    申请日：2013-12-13

    申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services

    发明人： Nicholas P. Restifo ,  Lydie Cassard ,  Zhiya Yu ,  Steven A. Rosenberg

    IPC分类号： C07K14/705 ,  G01N33/574 ,  C12N15/86 ,  C07K16/30 ,  C12N15/85

    CPC分类号： C07K14/70503 ,  A61K38/00 ,  C07K14/7051 ,  C07K16/30 ,  C12N15/85 ,  C12N15/86 ,  G01N33/57492

    摘要： The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.

    摘要翻译： 本发明提供了包含对癌抗原gp100具有抗原特异性的鼠T细胞受体（TCR）的人细胞，特别是人T细胞。 具有对gp100（SEQ ID NO：1）的氨基酸154-162具有抗原特异性的分离或纯化的TCR，以及相关多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体或抗原结合 其片段，缀合物和药物组合物。 本发明还提供了检测宿主中癌症存在的方法以及在宿主中治疗或预防癌症的方法，所述方法包括使用本文所述的本发明材料。

    SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA
    75.
    发明申请
    SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA 审中-公开
    使用干扰RNA沉默CSN5基因表达

    公开(公告)号：US20130178511A1

    公开(公告)日：2013-07-11

    申请号：US13551580

    申请日：2012-07-17

    申请人： Ian MacLachlan ,  Adam Judge ,  Snorri S. Thorgeirsson ,  Yun-Han Lee

    发明人： Ian MacLachlan ,  Adam Judge ,  Snorri S. Thorgeirsson ,  Yun-Han Lee

    IPC分类号： C12N15/113

    CPC分类号： C12N15/113 ,  A61K48/00 ,  C12N15/1135 ,  C12N2310/14

    摘要： The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.

    摘要翻译： 本发明提供包含靶向CSN5基因表达的核酸和使用这种组合物沉默CSN5基因表达的方法的组合物。 更具体地，本发明提供了沉默CSN5基因表达的未修饰和化学修饰的干扰RNA分子及其使用方法，例如用于治疗细胞增殖性疾病如癌症。 本发明还提供靶向CSN5基因表达的核酸 - 脂质颗粒，其包含干扰RNA分子，阳离子脂质，非阳离子脂质和任选的抑制颗粒聚集的共轭脂质。

    METHOD FOR DETECTION OF CANCER BASED ON SPATIAL GENOME ORGANIZATION
    77.
    发明申请
    METHOD FOR DETECTION OF CANCER BASED ON SPATIAL GENOME ORGANIZATION 有权
    基于空间基因组织检测癌症的方法

    公开(公告)号：US20110183334A1

    公开(公告)日：2011-07-28

    申请号：US13062247

    申请日：2009-09-03

    申请人： Thomas A. Misteli ,  Karen Meaburn

    发明人： Thomas A. Misteli ,  Karen Meaburn

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/112

    摘要： The invention provides methods of detecting abnormal cells in a sample using the radial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the radial position of one or more genes within the nucleus of a cell.

    摘要翻译： 本发明提供使用细胞核内的一个或多个基因的径向位置检测样品中的异常细胞的方法，以及使用这些方法检测异常细胞的试剂盒。 本发明还提供使用细胞核内的一个或多个基因的径向位置鉴定异常细胞的基因标记的方法。

    GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    78.
    发明申请
    GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE 有权
    GP100特异性T细胞受体及相关材料及其使用方法

    公开(公告)号：US20100015113A1

    公开(公告)日：2010-01-21

    申请号：US12522321

    申请日：2008-01-11

    申请人： Nicholas P. Restifo ,  Lydie Cassard ,  Zhiya Yu ,  Steven A. Rosenberg

    发明人： Nicholas P. Restifo ,  Lydie Cassard ,  Zhiya Yu ,  Steven A. Rosenberg

    IPC分类号： A61K35/12 ,  C12N5/08 ,  C07K14/725 ,  C07K16/18 ,  C07H21/04 ,  C12N15/63 ,  G01N33/53 ,  A61P35/04

    CPC分类号： C07K14/70503 ,  A61K38/00 ,  C07K14/7051 ,  C07K16/30 ,  C12N15/85 ,  C12N15/86 ,  G01N33/57492

    摘要： The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.

    摘要翻译： 本发明提供了包含对癌抗原gp100具有抗原特异性的鼠T细胞受体（TCR）的人细胞，特别是人T细胞。 具有对gp100（SEQ ID NO：1）的氨基酸154-162具有抗原特异性的分离或纯化的TCR，以及相关多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体或抗原结合 其片段，缀合物和药物组合物。 本发明还提供了检测宿主中癌症存在的方法以及在宿主中治疗或预防癌症的方法，所述方法包括使用本文所述的本发明材料。

    CHIMERIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    79.
    发明申请
    CHIMERIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE 审中-公开
    CHIMERIC T细胞受体及相关材料及使用方法

    公开(公告)号：US20090304657A1

    公开(公告)日：2009-12-10

    申请号：US12298927

    申请日：2007-05-03

    申请人： Richard A. Morgan ,  Cyrille J. Cohen ,  Steven A. Rosenberg

    发明人： Richard A. Morgan ,  Cyrille J. Cohen ,  Steven A. Rosenberg

    IPC分类号： A61K35/12 ,  C12N5/08 ,  C07K14/705 ,  C07H21/04 ,  C12N15/63 ,  C12N5/00

    CPC分类号： C07K14/7051 ,  C07K2319/00 ,  G01N33/6893

    摘要： The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR.

    摘要翻译： 本发明提供了包含人TCR的可变区和包含非人TCR的恒定区的至少胞外结构域的恒定区的嵌合T细胞受体（TCR）及其功能变体。 本发明还提供与本发明的TCR相关的多肽和蛋白质，以及编码TCR，多肽或蛋白质，重组表达载体和宿主细胞的核酸。 进一步提供的是与本发明的TCR相关的药物组合物和预防或治疗疾病例如感染性疾病，宿主中的癌症，检测宿主中的病变细胞的方法的方法以及改善宿主的生物活性的方法 TCR。